Major new cholesterol guidelines released in 2026 are fundamentally changing when doctors screen for heart disease risk, recommending testing as early as age 30 and even in childhood for those with family history. The updated recommendations from the American College of Cardiology and American Heart Association emphasize that preventing cardiovascular disease requires a lifetime approach, not just treating high cholesterol when you're older .

Why Are Doctors Starting Cholesterol Screening Earlier?

About 1 in 4 adults in the United States have elevated LDL (low-density lipoprotein) cholesterol, commonly called "bad" cholesterol . Research shows that long-term exposure to elevated LDL drives the buildup of plaque in arteries, a condition called atherosclerosis, which can eventually trigger heart attacks or strokes. The key insight from the new guidelines is that this damage accumulates over decades, so catching it early makes a real difference .

For people with a family history of heart disease or genetic conditions like familial hypercholesterolemia, screening should now begin around age 9 or earlier . For the general population, the guidelines recommend starting at age 30 using a new risk calculator called PREVENT (Predicting Risk of Cardiovascular Disease EVENTs), which estimates both 10-year and 30-year risk .

"Shifting the paradigm toward proactive prevention strategies earlier in life can meaningfully change the trajectory of cardiovascular disease and lead to better health outcomes for people decades later," explained Seth Martin, M.D., a cardiologist and member of the guideline writing committee.

Seth Martin, M.D., Cardiologist and Guideline Committee Member

What Makes the New Risk Calculator Different?

The previous risk calculator, used since 2018, focused mainly on 10-year risk for adults age 40 and older and relied on basic factors like age, cholesterol levels, and blood pressure. The new PREVENT calculator is a significant upgrade . It's designed for use starting at age 30 and includes additional measures such as blood sugar levels and kidney function. Most importantly, it's based on data from 6.6 million people, compared to just 26,000 in the earlier model, making it far more accurate .

This expanded approach means doctors can now identify people at risk much earlier and tailor treatment plans more precisely. The calculator also helps clinicians decide whether additional tests are needed to refine risk estimates .

How to Personalize Your Cholesterol Care

The new guidelines emphasize that cholesterol management is not one-size-fits-all. Instead of simply measuring LDL cholesterol, doctors now consider multiple factors to create a personalized prevention plan:

• Genetic Risk Factors: Testing for lipoprotein(a), or Lp(a), which is inherited and can raise heart disease risk by about 40% at levels of 125 nanomoles per liter and double the risk at 250 nanomoles per liter .
• Inflammation Markers: Measuring high-sensitivity C-reactive protein (hsCRP) to detect inflammation that may signal hidden cardiovascular risk even when cholesterol levels appear normal .
• Imaging Tests: Using coronary artery calcium scans to detect calcium deposits that signal plaque buildup in arteries, helping guide treatment decisions when risk remains uncertain .
• Life Events and Conditions: Considering family history, rheumatoid arthritis, early menopause, or pregnancy complications like preeclampsia or gestational diabetes, which all affect cardiovascular risk .
• Apolipoprotein B Testing: Measuring this protein, which may provide additional insight into cholesterol risk beyond standard LDL measurements .

"Cholesterol care isn't one-size-fits-all. These additional tools give us a clearer picture of each patient so we can make more personalized decisions," said Harmony R. Reynolds, M.D., director of NYU Langone's Cardiovascular Clinical Research Center.

Harmony R. Reynolds, M.D., Director of Cardiovascular Clinical Research Center at NYU Langone Health

What Are the New LDL Cholesterol Targets?

The guidelines establish specific LDL cholesterol goals depending on your risk level. For people without cardiovascular disease, LDL cholesterol levels below 100 mg/dL (milligrams per deciliter) are considered optimal . Those at intermediate risk should aim for levels below 70 mg/dL, while high-risk individuals should target less than 55 mg/dL . These targets are significantly lower than previous recommendations, reflecting evidence that aggressive cholesterol reduction prevents more heart attacks and strokes .

If lifestyle changes and statin therapy alone aren't enough to reach these goals, the guidelines now highlight several additional treatment options. These include ezetimibe, bempedoic acid, and injectable PCSK9 monoclonal antibodies, which are particularly important for individuals who don't respond well to statins or need multiple therapies .

Can a New Pill Offer Better Cholesterol Control?

Beyond the guideline updates, a promising experimental medication called enlicitide showed remarkable results in clinical trials. In a phase three trial involving 2,909 patients, enlicitide reduced LDL cholesterol by about 60% compared with a placebo after 24 weeks, with results holding steady over a yearlong follow-up period . This is the most significant reduction achieved with an oral medication since statins were developed decades ago .

What makes enlicitide notable is that it works similarly to injectable PCSK9 inhibitors, which bind to a protein called PCSK9 that reduces the liver's ability to clear cholesterol from the bloodstream. However, enlicitide is taken once daily as a pill, potentially making it more accessible than injections . The study population reflected real-world challenges: even though most participants were already taking high-intensity statins, their average LDL cholesterol was 96 mg/dL, far above the recommended 70 mg/dL for those with atherosclerosis .

"Fewer than half of patients with established atherosclerotic cardiovascular disease currently reach LDL cholesterol goals. An oral therapy this effective has the potential to dramatically improve our ability to prevent heart attacks and strokes on a population level," stated Ann Marie Navar, M.D., Ph.D., a cardiologist at UT Southwestern Medical Center who led the enlicitide study.

Ann Marie Navar, M.D., Ph.D., Cardiologist and Associate Professor at UT Southwestern Medical Center

What Role Does Lifestyle Still Play?

Despite the focus on new screening tools and medications, the guidelines emphasize that lifestyle remains foundational. Roughly 80% to 90% of cardiovascular disease is linked, at least in part, to factors people can modify . The core advice for maintaining heart health remains unchanged: eat a balanced diet, engage in regular physical activity, avoid tobacco, get enough sleep, and maintain a healthy weight .

"Diet and exercise are critically important, and these are habits we want to establish early and maintain over a lifetime," noted Harmony R. Reynolds, M.D.

Harmony R. Reynolds, M.D., Director of Cardiovascular Clinical Research Center at NYU Langone Health

The shift toward earlier screening and personalized prevention represents a fundamental change in how cardiologists approach heart disease. Rather than waiting until someone develops symptoms or reaches the highest risk category, doctors now have better tools to identify risk earlier and take action sooner. For most people, this means getting your cholesterol checked in your 30s, understanding your personal risk factors, and working with your doctor to create a prevention plan tailored to your specific situation. The goal is not just to lower cholesterol numbers, but to prevent heart disease from developing in the first place.